THE BIOARTIFICIAL PANCREAS: FROM CONCEPT TO CLINICAL REALITY
The lack of a graft makes the therapeutic approach to pancreatic islet transplantation limited to very few patients. The concept of the bioartificial pancreas aims to apply cell therapy to a greater number of patients by using other sources of cells that secrete insulin (stem cells and genetically modified cells).
The concept rests on an immunoisolation technique that:
To this end, the technique developed by CEED consists in a device for the macro-encapsulation of insulin-secreting cells (MAILPAN®) that is based on a semi-permeable membrane (permeable to insulin, oxygen glucose and other nutriments, but impermeable to the molecules involved in the reject).
After over 10 years of development, the project has been transferred to Defymed, a company whose objective is to develop and market this bioartificial pancreas.
CEED coordinates a European programme entitled BIOSID whose objective is to validate the functionality of this device in the clinic.